Edit Symbol List
Enter up to 25 symbols separated by commas or spaces in the text box below. These symbols will be available during your session for use on applicable pages.
Don't know the stock symbol? Use the symbol lookup tool.
Alphabetize the sort order of my symbols
DexCom, Inc. (DXCM)
Barclays Global Healthcare Conference
March 13, 2013 02:30 pm ET
Terrance Gregg - CEO
Kevin Sayer - President & Chief Operating Officer
Previous Statements by DXCM
» DexCom CEO Discusses Q4 2012 Results - Earnings Call Transcript
» DexCom CEO Discusses Q3 2010 Results - Earnings Call Transcript
» DexCom, Inc.Q2 2010 Earnings Call Transcript
» DexCom, Inc. Q1 2010 Earnings Call Transcript
Sure. Well, as you know we got approval for fourth-generation glucose sensor last October, so we've been in that full launch mode since then. Here we are into the last weeks of the quarter and excited. That's the way I can describe it. Demand has remained strong. We live in a cyclical world with the DNA business whereas the first quarter sequentially after strong fourth quarter tends to be weaker. We certainly expect some of that, but as looking at the pipeline, what we pipeline having to do with the number of patients that have asked for the product going, go through benefits analysis for them. That remains as strong as ever we've ever seen.
It's certainly stronger than any first quarter following a strong fourth quarter, so all of that, and I'll have Kevin talk about margin, but all of that drives to volume and volume drives to improved margins. So, we're exceeding our expectations in the performance of product at the user level and at the prescriber level, and so we think that this really meets the criteria what CGM has been expected to be over the years, but really unfortunately including us failed to reach that criteria until the Gen4.
On the margin side, our fourth-quarter margins were strong due to a number of factors. The volumes that we generated, a number of units that we produced, not just sales, but our manufacturing lines were very high in anticipation of the product launch as well.
As we move into the first quarter, those were offset by startup yields, which were acceptable as we planned on. As we moved into the first quarter so far, our margins targets, we're hitting them, our yields have been very strong on the Gen4 product. It was originally designed as a cost savings product evolution on our product pipeline and those cost savings, they are coming to fruition as we go.
You've been working on some pediatric communication, so?
We filed our pediatric labeling indication in the first quarter with the agency, so we will go from there.
In Europe, you received CE Mark in the first quarter. Is that correct?
Yes. We just felt the advanced technology meeting was in Paris two weeks ago. We had two sets of banners. One without pediatric indication and one with pediatric indication, we got it two days before going into the meeting, so we're now in the process of doing the necessary labeling updates and our goal is to allow our distributors who represent us in the European sector to begin calling on that population early in the second quarter.
Can you just help us frame that additional opportunity with having that indication in Europe and in the U.S.?
Sure. Well, let's start with the U.S., because that's still our largest market, and today there are somewhere between 800 and 1,000 pediatric endocrinologists that we don’t call. We do have an installed base. Let's say roughly 10% of our population are individuals less than 17 years of age, but that’s off label use, therefore we don’t compensate our salespeople for that placement on that group of patients. We certainly don’t call on physicians to prescribe. It's the physician decision or the parent's decision, so we think this opens up a whole new opportunity. We scale our sales force up by 20 new territories this quarter in anticipation of that as well as better geographic satisfaction to the prescribers that we're calling on today, and so we think that's an uptick.
If you looked at our guidance, for the year about $120 million to $130 million, 35% to 40% over last year’s product revenue certainly some of that higher end towards the upper range of the guidance is based on the expectation of a pediatric claim approval later in the year.
And you mentioned most of your businesses in the U.S., can you talk a little bit about the strategy outside the U.S.
Right now there is not strong reimbursement any place outside the U.S. and so it’s been used largely by physicians in clinics and by people who do cash pay, but our businesses is growing very consistently, and as we've disclosed on our calls our U.S. revenues are nearing 10% of the total pie. We'll continue to grow that more rapidly than the growth the U.S., but proportionate when you get into numbers. U.S. will still be bigger.
Our approach right now is we are not going direct anywhere. We have a very strong network of distributors who distribute our products in the various geographies and we'll add several new countries this year. We'll probably double the number of countries we are in from today by the end of this year, not all of them are huge, but nevertheless every time we do it more translation this it's more manual it's more operational issues as well, so we are expanding internationally. We have good distribution partners. Roche is a very good distribution partner for us in some of these geographies as well. They have been very instrumental in helping us for our business. It is a good network and it's a good way for us to start.